NASDAQ:INO

Inovio Pharmaceuticals (INO) Stock Forecast, Price & News

$0.38

+0.01 (+2.69%)

(As of 09/27/2023 ET)

Compare

Today's Range: $0.38
▼
$0.38
50-Day Range: $0.38
▼
$0.54
52-Week Range: $0.38
▼
$2.61

Volume: 930,099 shs
Average Volume: 5.82 million shs
Market Capitalization: $102.33 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.00

Inovio Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Reduce
1.67 Rating Score
Upside/Downside: 424.0% Upside
$2.00 Price Target
Short Interest: Healthy
5.83% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.52
Upright™ Environmental Score
News Sentiment: 0.81
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.52) to ($0.30) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

377th out of 976 stocks

Surgical & Medical Instruments Industry

46th out of 99 stocks

2.8

Analyst's Opinion

Consensus Rating
Inovio Pharmaceuticals has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no buy ratings, 2 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $2.00, Inovio Pharmaceuticals has a forecasted upside of 424.0% from its current price of $0.38.
Amount of Analyst Coverage
Inovio Pharmaceuticals has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
5.83% of the outstanding shares of Inovio Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Inovio Pharmaceuticals has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Inovio Pharmaceuticals has recently decreased by 6.41%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Inovio Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Inovio Pharmaceuticals does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Inovio Pharmaceuticals has received a 78.16% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for infectious diseases", "Clinical research services for cancer", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Inovio Pharmaceuticals is -0.52.

2.7

News and Social Media Coverage

News Sentiment
Inovio Pharmaceuticals has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Inovio Pharmaceuticals this week, compared to 3 articles on an average week.
Search Interest
Only 6 people have searched for INO on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.
MarketBeat Follows
10 people have added Inovio Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 43% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Inovio Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.00% of the stock of Inovio Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 26.79% of the stock of Inovio Pharmaceuticals is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Inovio Pharmaceuticals are expected to grow in the coming year, from ($0.52) to ($0.30) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Inovio Pharmaceuticals is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Inovio Pharmaceuticals is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Inovio Pharmaceuticals has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Inovio Pharmaceuticals (NASDAQ:INO) Stock

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia, including cervical, vulvar, and anal dysplasia and is under phase II/III clinical trials; INO-3107 for HPV-related recurrent respiratory rapillomatosis and is under Phase 1/2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under phase 1b trial; and INO-4500 vaccine for lassa fever, which is under phase 1b trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

INO Price History

30 days | 90 days | 365 days | Advanced Chart

INO Stock News Headlines

September 27, 2023 | finance.yahoo.com

Geneos Therapeutics Closes its Series A3 Financing With Investment of $5 Million

September 26, 2023 | americanbankingnews.com

Inovio Pharmaceuticals (NASDAQ:INO) Research Coverage Started at StockNews.com

September 27, 2023 | Chaikin Analytics (Ad)

Something is Coming for America's Top Stock

This stock has already doubled this year - but it could hurt your portfolio if you hold it much longer. Learn why here.

September 21, 2023 | marketwatch.com

Inovio Pharmaceuticals Inc. stock falls Thursday, still outperforms market

September 18, 2023 | americanbankingnews.com

Inovio Pharmaceuticals (NASDAQ:INO) Now Covered by StockNews.com

September 9, 2023 | msn.com

Inovio Pharmaceuticals: Tightening The Ship, Finding An Inflection Point

September 7, 2023 | finance.yahoo.com

INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

August 29, 2023 | finance.yahoo.com

INOVIO to Present at the H.C. Wainwright 25th Annual Global Investment Conference

September 27, 2023 | Chaikin Analytics (Ad)

Something is Coming for America's Top Stock

This stock has already doubled this year - but it could hurt your portfolio if you hold it much longer. Learn why here.

August 11, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Hold Rating on Inovio Pharmaceuticals (INO)

August 10, 2023 | finanznachrichten.de

INOVIO Pharmaceuticals, Inc.: INOVIO Announces Second Quarter 2023 Financial Results and Provides Strategic Update

August 9, 2023 | finance.yahoo.com

Inovio Pharmaceuticals (INO) Q2 2023 Earnings Call Transcript

August 1, 2023 | bizjournals.com

Inovio Pharmaceuticals cuts 30% of staff in third round of layoffs in 13 months

July 28, 2023 | thestreet.com

Inovio Pharmaceuticals (INO) Stock Up, Begins Recruitment for MERS Vaccine Trial

July 26, 2023 | finance.yahoo.com

INOVIO to Report Second Quarter 2023 Financial Results on August 9, 2023

June 23, 2023 | finanznachrichten.de

Inovio Pharmaceuticals, Inc.: INOVIO Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

June 23, 2023 | finance.yahoo.com

INOVIO Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

June 19, 2023 | thestreet.com

Inovio's CEO Defends Swine Flu Drug (Part 2)

June 14, 2023 | marketwatch.com

Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors

May 25, 2023 | finance.yahoo.com

INOVIO to Present at the 2023 Jefferies Healthcare Conference

May 24, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Hold Rating on Inovio Pharmaceuticals (INO)

May 24, 2023 | finance.yahoo.com

INOVIA's (INO) Rare Disease Drug Gets EC's Orphan Tag, Stock Up

May 24, 2023 | markets.businessinsider.com

Inovio : EU Grants Orphan Drug Designation For INO-3107

May 23, 2023 | finance.yahoo.com

INOVIO Announces Orphan Drug Designation for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

May 16, 2023 | marketwatch.com

2023-2029 "Needle Free Drug Delivery Devices Market" volume sale, Trends and Market Overview | Report Reviewed by Experts

May 15, 2023 | finance.yahoo.com

All You Need to Know About Inovio (INO) Rating Upgrade to Buy

May 15, 2023 | finance.yahoo.com

These Analysts Think Inovio Pharmaceuticals, Inc.'s (NASDAQ:INO) Sales Are Under Threat

See More Headlines

Receive INO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inovio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

INO Company Calendar

Last Earnings: 8/09/2023
Today: 9/27/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:INO
CUSIP: N/A
CIK: 1055726
Web: www.inovio.com
Phone: (267) 440-4200
Fax: 267-440-4242
Employees: 135
Year Founded: 1979

Price Target and Rating

Average Stock Price Forecast: $2.00
High Stock Price Forecast: $2.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +433.0%
Consensus Rating: Reduce
Rating Score (0-4): 1.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.65)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-279,820,000.00
Net Margins: -1,750.84%
Pretax Margin: -1,750.84%
Return on Equity: -78.56%
Return on Assets: -54.33%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.91
Quick Ratio: 3.91

Sales & Book Value

Annual Sales: $10.26 million
Price / Sales: 9.80
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.89 per share
Price / Book: 0.42

Miscellaneous

Outstanding Shares: 268,080,000
Free Float: 262,714,000
Market Cap: $100.58 million
Optionable: Optionable
Beta: 0.97

Social Links

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Dr. Jacqueline E. Shea Ph.D. (Age 57)
CEO, Pres & Director
Comp: $1.08M

Mr. Peter D. Kies (Age 60)
Chief Financial Officer
Comp: $688.72k

Dr. Laurent M. Humeau Ph.D. (Age 56)
Chief Scientific Officer
Comp: $673.59k

Thomas Hong
Mang. of Investor Relations

Mr. Robert L. Crotty J.D. (Age 49)
Gen. Counsel & Chief Compliance Officer

Mr. E. J. Brandreth MBA
Sr. VP of Quality Assurance

Dr. Jeffrey Skolnik
Sr. VP of Clinical Devel.

Mr. Robert J. Juba Jr.
Sr. VP of Biological Manufacturing & Clinical Supply Management

Mr. Stephen Kemmerrer M.B.A.
P.E., Sr. VP of Engineering Devel.

Mr. Shawn D. Bridy M.A.
M.B.A., MA, MBA, Sr. VP of Bus. Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

INO Stock - Frequently Asked Questions

Should I buy or sell Inovio Pharmaceuticals stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last year. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" INO shares.
View INO analyst ratings or view top-rated stocks.
What is Inovio Pharmaceuticals' stock price forecast for 2023?: 3 analysts have issued 12-month price objectives for Inovio Pharmaceuticals' shares. Their INO share price forecasts range from $2.00 to $2.00. On average, they expect the company's stock price to reach $2.00 in the next year. This suggests a possible upside of 433.0% from the stock's current price.
View analysts price targets for INO or view top-rated stocks among Wall Street analysts.
How have INO shares performed in 2023?: Inovio Pharmaceuticals' stock was trading at $1.56 at the start of the year. Since then, INO shares have decreased by 75.9% and is now trading at $0.3752.
View the best growth stocks for 2023 here.
Are investors shorting Inovio Pharmaceuticals?: Inovio Pharmaceuticals saw a decline in short interest in the month of September. As of September 15th, there was short interest totaling 15,630,000 shares, a decline of 6.4% from the August 31st total of 16,700,000 shares. Based on an average daily trading volume, of 4,300,000 shares, the short-interest ratio is currently 3.6 days.
View Inovio Pharmaceuticals' Short Interest.
When is Inovio Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our INO earnings forecast.
How were Inovio Pharmaceuticals' earnings last quarter?: Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced its earnings results on Wednesday, August, 9th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.01. The biopharmaceutical company had revenue of $0.23 million for the quarter, compared to analysts' expectations of $0.20 million. Inovio Pharmaceuticals had a negative trailing twelve-month return on equity of 78.56% and a negative net margin of 1,750.84%. During the same period in the previous year, the company earned ($0.46) EPS.
When did Inovio Pharmaceuticals' stock split?: Inovio Pharmaceuticals shares reverse split before market open on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2014. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.
What is J. Joseph Kim's approval rating as Inovio Pharmaceuticals' CEO?: 12 employees have rated Inovio Pharmaceuticals Chief Executive Officer J. Joseph Kim on Glassdoor.com. J. Joseph Kim has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Inovio Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Novavax (NVAX), Moderna (MRNA), Gilead Sciences (GILD), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE), Micron Technology (MU), Sorrento Therapeutics (SRNE) and Vaxart (VXRT).
What is Inovio Pharmaceuticals' stock symbol?: Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."
Who are Inovio Pharmaceuticals' major shareholders?: Inovio Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.32%), Renaissance Technologies LLC (2.07%), Geode Capital Management LLC (1.09%), Charles Schwab Investment Management Inc. (0.48%), State Street Corp (0.33%) and Y Intercept Hong Kong Ltd (0.24%). Insiders that own company stock include David B Weiner, David B Weiner, Jacqueline Elizabeth Shea, Jong Joseph Kim, Laurent Humeau, Lota S Zoth, Peter Kies and Simon X Benito.
View institutional ownership trends.
How do I buy shares of Inovio Pharmaceuticals?: Shares of INO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Inovio Pharmaceuticals' stock price today?: One share of INO stock can currently be purchased for approximately $0.38.
How much money does Inovio Pharmaceuticals make?: Inovio Pharmaceuticals (NASDAQ:INO) has a market capitalization of $100.58 million and generates $10.26 million in revenue each year. The biopharmaceutical company earns $-279,820,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis.
How many employees does Inovio Pharmaceuticals have?: The company employs 135 workers across the globe.
How can I contact Inovio Pharmaceuticals?: Inovio Pharmaceuticals' mailing address is 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462. The official website for the company is www.inovio.com. The biopharmaceutical company can be reached via phone at (267) 440-4200, via email at investor.relations@inovio.com, or via fax at 267-440-4242.

This page (NASDAQ:INO) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial